Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer

BACKGROUND: TP53 mutations are the most prevalent mutations detected in non‐small‐cell lung cancer (NSCLC) and have been revealed as a negative prognostic biomarker of outcome. The impact of concomitant TP53 mutations in ALK‐rearranged NSCLC remains uncertain. METHODS: Tumor samples from 64 ALK‐rear...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Zhang, Fanshuang, Li, Yan, Yang, Guangjian, Li, Wenbin, Ying, Jianming, Gao, Shugeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488212/
https://www.ncbi.nlm.nih.gov/pubmed/30843662
http://dx.doi.org/10.1002/cam4.2043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488212/
https://www.ncbi.nlm.nih.gov/pubmed/30843662
http://dx.doi.org/10.1002/cam4.2043

Ejemplares similares